Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature

Main Article Content

Elisa Buzzatti
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome

Cristina Mauro
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome

Caterina Botti
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome

Roberta Presicci
Department of Medical Sciences and Public Health, University of Cagliari, Cagliari

Giovangiacinto Paterno
UOSD Mieloproliferative, Policlinico Tor Vergata, Rome

Raffaele Palmieri
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Carmelo Gurnari
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Flavia Mallegni
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Elisa Meddi
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Federico Moretti
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Lucia Cardillo
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Valeria Mezzanotte
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Kristian Taka
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Lucrezia De Marchi
Department of Biomedicine and Prevention, University Tor Vergata of Rome

Luca Maurillo
UOSD Mieloproliferative, Policlinico Tor Vergata, Rome

Francesco Buccisano
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome

Adriano Venditti
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome

Maria Ilaria Del Principe
Department of Biomedicine and Prevention, University Tor Vergata of Rome, Rome

Keywords

Acute Myeloid leukemia, Venetoclax, Hypomethylating agents, extramedullary localization

Abstract

Leukemia cutis (LC) is a rare extramedullary localization of acute myeloid leukemia (AML). LC management generally relies on AML treatment, namely intensive chemotherapy (IC). In frail patients with LC, viable options are hypomethylating agents (HMA) associated with Venetoclax, but literature about their use is scarce. Here, we report our experience and a short review of the previous cases of LC treated with HMA plus Venetoclax to underline the efficacy of such treatment in LC patients unsuitable for IC.

Downloads

Download data is not yet available.


Abstract 49
PDF Downloads 37
HTML Downloads 1

Article Sidebar

PDF HTML
Published
Feb 27, 2025
DOI https://doi.org/10.4084/MJHID.2025.013

Article Details

How to Cite

Buzzatti, E. (2025) “Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature”, Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025013. doi: 10.4084/MJHID.2025.013.
Issue
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Case Reports
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.